# Isenolic (Olive Leaf Extract)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/isenolic
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-01
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Olea europaea leaf extract, Standardized olive leaf extract, Elenolic acid-rich olive extract, OLE (Olive Leaf Extract), Pharmactive olive leaf extract, Secoiridoid-containing olive extract, 4% EA olive leaf extract, Oleuropein-derived extract

## Overview

Olive leaf extract contains oleuropein as its primary bioactive compound, which exerts antiviral effects by inhibiting neuraminidase enzymes critical to viral replication and spread. Standardized formulations have demonstrated dose-dependent suppression of influenza A (H3N2) activity in laboratory models, positioning it as a candidate [immune support](/ingredients/condition/immune-support) ingredient.

## Health Benefits

• Antiviral activity against influenza A (H3N2) through neuraminidase inhibition (preliminary evidence from in vitro studies)
• Dose-dependent viral replication inhibition with IC50 of 65.5 µg/ml for 8% EA formulation (in vitro evidence)
• Cell viability preservation under viral infection conditions (CC50 149.7 µg/ml, in vitro data)
• Multi-target antiviral mechanisms including blocking viral entry and replication (in vitro studies only)
• Potential [immune support](/ingredients/condition/immune-support) through stimulation of phagocytosis (preliminary in vitro evidence)

## Mechanism of Action

Oleuropein and its metabolite elenolic acid inhibit viral neuraminidase, the enzyme influenza A uses to cleave sialic acid residues and release newly formed virions from host cells, effectively trapping the virus and limiting spread. An 8% elenolic acid (EA) standardized formulation achieved an IC50 of 65.5 µg/ml in vitro, indicating potent dose-dependent neuraminidase inhibition. Oleuropein also appears to modulate NF-κB signaling pathways, contributing to reduced [inflammatory](/ingredients/condition/inflammation) cytokine expression during viral challenge.

## Clinical Summary

Current evidence for Isenolic olive leaf extract's antiviral effects is limited to in vitro (cell-based) studies, with no published human randomized controlled trials specifically evaluating this standardized formulation for influenza. The in vitro data demonstrated an IC50 of 65.5 µg/ml for neuraminidase inhibition using an 8% elenolic acid formulation, with measurable preservation of host cell viability under H3N2 viral infection conditions. While broader olive leaf extract research includes small human trials on [blood pressure](/ingredients/condition/heart-health) and [oxidative stress](/ingredients/condition/antioxidant) markers, direct extrapolation to antiviral [immune support](/ingredients/condition/immune-support) requires caution. The evidence base is preliminary and promising but insufficient to draw definitive clinical conclusions without controlled human trials.

## Nutritional Profile

{"bioactive_compounds": {"oleuropein": "20-25% of extract", "hydroxytyrosol": "1-2% of extract", "tyrosol": "0.5-1% of extract", "flavonoids": "0.5-1% of extract"}, "macronutrients": {"fiber": "Negligible", "protein": "Negligible", "fat": "Negligible", "carbohydrates": "Negligible"}, "micronutrients": {"vitamins": "Negligible", "minerals": "Negligible"}, "bioavailability_notes": "Oleuropein and hydroxytyrosol are the primary bioactive compounds with moderate bioavailability. The presence of other polyphenols may enhance absorption."}

## Dosage & Preparation

No human dosage ranges have been established. In vitro studies used 6-150 µg/ml concentrations in cell culture, with optimal activity at IC50 of 65.5 µg/ml for 8% EA formulation. Standardization is 4% or 8% elenolic acid by HPLC. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Olive leaf extract is generally well tolerated at typical supplemental doses (500–1000 mg/day of standardized extract), with the most commonly reported side effect being mild gastrointestinal discomfort including nausea or stomach cramping. Oleuropein may potentiate the effects of antihypertensive medications and anticoagulants such as warfarin due to its vasodilatory and platelet-modulating properties, requiring caution in patients on these drugs. Individuals taking antidiabetic medications should monitor [blood glucose](/ingredients/condition/weight-management) closely, as olive leaf extract has demonstrated hypoglycemic activity in preclinical models. Safety data during pregnancy and lactation is insufficient, so use is not recommended in these populations without medical supervision.

## Scientific Research

Evidence is limited to in vitro studies with no human clinical trials identified. One key study (PMC8641117) tested Isenolic on MDCK-SIAT1 cells infected with influenza A (H3N2), showing the 8% EA formulation had superior neuraminidase inhibition compared to 4% EA (IC50 65.5 µg/ml vs. 171.4 µg/ml; P<0.01).

## Historical & Cultural Context

No traditional use information for Isenolic specifically was provided in the research, as it is a modern branded extract. While olive leaf (Olea europaea) has traditional uses, specific historical context for this standardized extract is absent from available sources.

## Synergistic Combinations

Vitamin C, Vitamin D3, Zinc, Elderberry Extract, Quercetin

## Frequently Asked Questions

### What is Isenolic olive leaf extract and how does it work?

Isenolic is a standardized olive leaf extract formulation containing 8% elenolic acid (EA), the bioactive metabolite of oleuropein. It works primarily by inhibiting viral neuraminidase enzymes that influenza A (H3N2) requires to replicate and spread between cells, achieving an IC50 of 65.5 µg/ml in laboratory studies. This mechanism is similar in concept to pharmaceutical neuraminidase inhibitors like oseltamivir, though clinical equivalency has not been established.

### What does IC50 of 65.5 µg/ml mean for olive leaf extract's antiviral effect?

IC50 refers to the concentration of a compound needed to inhibit 50% of the target enzyme's activity — in this case, neuraminidase from influenza A (H3N2). An IC50 of 65.5 µg/ml for the 8% elenolic acid formulation indicates moderate potency in a cell culture setting. This figure is derived from in vitro data only, so whether equivalent inhibitory concentrations are achievable in human tissue after oral dosing remains unconfirmed.

### Has olive leaf extract been tested in human clinical trials for flu or immune support?

No published human clinical trials have specifically evaluated the Isenolic formulation for influenza or antiviral immune support as of current evidence. Broader olive leaf extract research has included small human trials (typically 20–60 participants) examining cardiovascular and antioxidant outcomes, but these used different standardizations. The antiviral data supporting Isenolic remains at the in vitro stage, meaning human efficacy and optimal dosing have not been confirmed.

### Can olive leaf extract interact with medications?

Yes, olive leaf extract has clinically relevant interaction potential with several drug classes. Oleuropein may enhance the blood pressure-lowering effects of antihypertensives, potentially causing hypotension, and may increase bleeding risk when combined with anticoagulants like warfarin or antiplatelet drugs such as aspirin. It also exhibits hypoglycemic activity in preclinical models, so patients on metformin, insulin, or sulfonylureas should monitor glucose levels carefully when adding this supplement.

### What is the recommended dosage of olive leaf extract for immune support?

No clinically validated dosage has been established for Isenolic specifically, since human trials are lacking. General supplemental use of standardized olive leaf extract ranges from 500 mg to 1000 mg per day of an extract standardized to 15–20% oleuropein or its equivalents. The in vitro studies used an 8% elenolic acid formulation at concentrations of 65.5 µg/ml, but translating this directly into a human oral dose requires pharmacokinetic data that is not yet publicly available for this product.

### Is Isenolic olive leaf extract safe for children to take?

While olive leaf extract is generally recognized as safe from food sources, there is limited clinical data on Isenolic supplementation specifically in pediatric populations. Parents should consult with a healthcare provider before giving Isenolic to children, as appropriate dosing for younger age groups has not been established in clinical trials. The safety profile in children cannot be confirmed without dedicated pediatric studies.

### How does Isenolic compare to other antiviral herbal supplements like elderberry or echinacea?

Isenolic's antiviral mechanism targets viral neuraminidase through in vitro inhibition, whereas elderberry and echinacea work through different pathways (polysaccharides and immune modulation respectively). Unlike Isenolic, elderberry and echinacea have more extensive human clinical trial data, though Isenolic's specific IC50 measurements provide detailed mechanistic evidence in laboratory conditions. Direct head-to-head clinical comparisons between these ingredients have not been conducted.

### Does the 8% ellagic acid formulation in Isenolic affect its bioavailability compared to whole olive leaf extract?

The 8% ellagic acid (EA) formulation in Isenolic is standardized to provide consistent neuraminidase inhibitory activity, with the IC50 of 65.5 µg/ml measured specifically for this concentration. Standardized extracts typically offer more predictable absorption and biological activity than whole leaf preparations, though human bioavailability studies for Isenolic have not been published. The standardization ensures dose-dependent viral replication inhibition as demonstrated in in vitro models.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*